High prevalence of dyslipidaemia among persons with diabetes mellitus and hypertension at a tertiary hospital in Blantyre, Malawi.
Diabetes mellitus
Dyslipidaemia
Hypertension
Malawi
Queen Elizabeth Central Hospital
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
22 12 2022
22 12 2022
Historique:
received:
02
11
2022
accepted:
14
12
2022
entrez:
21
12
2022
pubmed:
22
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Dyslipidaemia drives the process of atherosclerosis, and hence a significant modifiable risk factor complicating hypertension and diabetes. In Malawi, the prevalence, screening and management of dyslipidaemia among persons with diabetes mellitus have not been reported. This study aimed to investigate the prevalence, biochemical characteristics, screening and management practices for dyslipidaemia among persons with diabetes mellitus, hypertension, and diabetes mellitus and hypertension comorbidity at Queen Elizabeth Central hospital in Blantyre, Malawi. This was a cross-sectional study conducted in 2021. A total of 256 adult participants (diabetes mellitus = 100); hypertension = 100; both conditions = 56) were included. Medical data and anthropometric measurements were recorded. Blood samples were analysed for HbA1C and serum lipids. Associated risk factors for dyslipidaemia were also assessed. Dyslipidaemia was prevalent in 58%, 55%, and 70% of participants with diabetes mellitus, hypertension, and both conditions. Low-density lipoprotein cholesterol (LDL-C) dyslipidaemia was the most common in all participant groups. Participants with both diabetes and hypertension had 2.4 times (95% CI 1.2-4.6) increased risk of LDL-C dyslipidaemia than those with diabetes alone (p < 0.02). Being overweight or obese and age over 30 years were risk factors for dyslipidaemia in participants with diabetes mellitus alone (OR 1.3 (95% CI 1.1-1.6), p < 0.04, and OR 2.2 (95% CI 1.2-4.7) (p < 0.01), respectively. Overweight and obesity predicted LDL-C dyslipidaemia in hypertensive patients (OR 3.5 (95% CI 1.2-9.9) p < 0.001). Poorly controlled hypertension and the use of beta-blockers and thiazide diuretics predicted dyslipidaemia among patients with both diabetes mellitus and hypertension (OR 6.50 CI 1.45-29.19; and OR 5.20 CI 1.16-23.36 respectively). None of the participants had a lipogram performed before the study or were on lipid-lowering therapy. Dyslipidaemia with LDL-C derangement was highly prevalent, especially in individuals with both diabetes mellitus and hypertension, and there was absent use of lipid-lowering therapy. Screening and managing dyslipidaemia should be reinforced to reduce the risk of cardiovascular complications in this population at increased risk.
Sections du résumé
BACKGROUND
Dyslipidaemia drives the process of atherosclerosis, and hence a significant modifiable risk factor complicating hypertension and diabetes. In Malawi, the prevalence, screening and management of dyslipidaemia among persons with diabetes mellitus have not been reported. This study aimed to investigate the prevalence, biochemical characteristics, screening and management practices for dyslipidaemia among persons with diabetes mellitus, hypertension, and diabetes mellitus and hypertension comorbidity at Queen Elizabeth Central hospital in Blantyre, Malawi.
METHODS
This was a cross-sectional study conducted in 2021. A total of 256 adult participants (diabetes mellitus = 100); hypertension = 100; both conditions = 56) were included. Medical data and anthropometric measurements were recorded. Blood samples were analysed for HbA1C and serum lipids. Associated risk factors for dyslipidaemia were also assessed.
RESULTS
Dyslipidaemia was prevalent in 58%, 55%, and 70% of participants with diabetes mellitus, hypertension, and both conditions. Low-density lipoprotein cholesterol (LDL-C) dyslipidaemia was the most common in all participant groups. Participants with both diabetes and hypertension had 2.4 times (95% CI 1.2-4.6) increased risk of LDL-C dyslipidaemia than those with diabetes alone (p < 0.02). Being overweight or obese and age over 30 years were risk factors for dyslipidaemia in participants with diabetes mellitus alone (OR 1.3 (95% CI 1.1-1.6), p < 0.04, and OR 2.2 (95% CI 1.2-4.7) (p < 0.01), respectively. Overweight and obesity predicted LDL-C dyslipidaemia in hypertensive patients (OR 3.5 (95% CI 1.2-9.9) p < 0.001). Poorly controlled hypertension and the use of beta-blockers and thiazide diuretics predicted dyslipidaemia among patients with both diabetes mellitus and hypertension (OR 6.50 CI 1.45-29.19; and OR 5.20 CI 1.16-23.36 respectively). None of the participants had a lipogram performed before the study or were on lipid-lowering therapy.
CONCLUSIONS
Dyslipidaemia with LDL-C derangement was highly prevalent, especially in individuals with both diabetes mellitus and hypertension, and there was absent use of lipid-lowering therapy. Screening and managing dyslipidaemia should be reinforced to reduce the risk of cardiovascular complications in this population at increased risk.
Identifiants
pubmed: 36544081
doi: 10.1186/s12872-022-03011-y
pii: 10.1186/s12872-022-03011-y
pmc: PMC9771776
doi:
Substances chimiques
Cholesterol, LDL
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
557Subventions
Organisme : NCI NIH HHS
ID : P20 CA210285
Pays : United States
Organisme : Medical Research Council
ID : MR/P020526/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206545/Z/17/Z
Pays : United Kingdom
Organisme : FIC NIH HHS
ID : D43 TW010060
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : U24 HL136791
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
BMC Endocr Disord. 2021 Aug 8;21(1):159
pubmed: 34365977
Hormones (Athens). 2018 Mar;17(1):61-67
pubmed: 29858856
Endocr Pract. 2017 Apr;23(Suppl 2):1-87
pubmed: 28437620
Curr Cardiol Rev. 2018 Mar 14;14(1):4-14
pubmed: 28990536
Metabol Open. 2021 Jul 17;11:100108
pubmed: 34355158
N Engl J Med. 2015 Jun 18;372(25):2387-97
pubmed: 26039521
BMC Endocr Disord. 2015 Apr 04;15:18
pubmed: 25881080
BMC Public Health. 2011 Aug 11;11:641
pubmed: 21834954
Glob Heart. 2019 Jun;14(2):109-118
pubmed: 31324364
Cardiovasc J Afr. 2019 Jan/Feb 23;30(1):15-23
pubmed: 30720848
Afr J Lab Med. 2015 Nov 18;4(1):
pubmed: 27213139
J Am Coll Cardiol. 2015 Apr 7;65(13):1361-1368
pubmed: 25835448
JAMA Cardiol. 2018 Sep 1;3(9):823-828
pubmed: 30073316
Clin Chim Acta. 2016 Jul 1;458:144-53
pubmed: 27178483
Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):241-244
pubmed: 31748177
J Diabetes Complications. 2022 Feb;36(2):108101
pubmed: 34922811
Lancet. 2016 Jan 2;387(10013):61-9
pubmed: 26498706
Nutr Diabetes. 2014 Aug 18;4:e130
pubmed: 25133442
Diabetes Ther. 2016 Jun;7(2):203-19
pubmed: 27056202
Malawi Med J. 2018 Jun;30(2):79-85
pubmed: 30627333
J Lipids. 2019 Apr 30;2019:2517013
pubmed: 31183219
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
Lancet Glob Health. 2018 Sep;6(9):e998-e1007
pubmed: 30103999
PLoS One. 2014 Nov 04;9(11):e111812
pubmed: 25369455
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
Pan Afr Med J. 2021 May 04;39:11
pubmed: 34394802
Med Clin North Am. 2017 Jul;101(4):689-699
pubmed: 28577620
N Engl J Med. 2019 Oct 17;381(16):1557-1567
pubmed: 31618541
Cardiovasc Diagn Ther. 2014 Oct;4(5):357-64
pubmed: 25414822
J Clin Lipidol. 2016 May-Jun;10(3):472-89
pubmed: 27206934
Arch Endocrinol Metab. 2018 Oct;62(5):552-559
pubmed: 30462809
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290
Hypertension. 2015 Jan;65(1):108-14
pubmed: 25331850
South Afr J HIV Med. 2017 Jul 15;18(1):776
pubmed: 29568644
Biochem Genet. 2021 Jun;59(3):781-798
pubmed: 33543406
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Ann Pharmacother. 2018 Feb;52(2):175-184
pubmed: 28915766
S Afr Med J. 2018 Oct 26;108(11b):973-1000
pubmed: 30421699
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
BMC Cardiovasc Disord. 2017 Jun 17;17(1):160
pubmed: 28623902
J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209
pubmed: 30423391
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
J Am Coll Cardiol. 2019 Sep 10;74(10):e177-e232
pubmed: 30894318
Blood Purif. 1999;17(2-3):66-78
pubmed: 10449864